FTC challenges Amgen patent strategy; Moderna-Merck cancer vaccine progress update

The FTC has initiated a challenge against Amgen's patent strategies regarding the drug Enbrel, signaling increased regulatory scrutiny of pharmaceutical intellectual property practices. Simultaneously, the development of the Moderna-Merck personalized cancer vaccine continues to face a complex clinical and regulatory pathway. These developments highlight ongoing tensions between pharmaceutical patent protection and market competition.